200 related articles for article (PubMed ID: 14611841)
1. MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
Marcq V; Mirand C; Decarme M; Emonard H; Hornebeck W
Bioorg Med Chem Lett; 2003 Sep; 13(17):2843-6. PubMed ID: 14611841
[TBL] [Abstract][Full Text] [Related]
2. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E
Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
5. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
6. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.
Levin JI; Du MT; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Moy FJ; Powers R; Jin G; Cowling R; Skotnicki JS
Bioorg Med Chem Lett; 2001 Jan; 11(2):235-8. PubMed ID: 11206467
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).
Fray MJ; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):571-4. PubMed ID: 11229774
[TBL] [Abstract][Full Text] [Related]
8. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
Steinman DH; Curtin ML; Garland RB; Davidsen SK; Heyman HR; Holms JH; Albert DH; Magoc TJ; Nagy IB; Marcotte PA; Li J; Morgan DW; Hutchins C; Summers JB
Bioorg Med Chem Lett; 1998 Aug; 8(16):2087-92. PubMed ID: 9873491
[TBL] [Abstract][Full Text] [Related]
9. Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.
Campbell DA; Xiao XY; Harris D; Ida S; Mortezaei R; Ngu K; Shi L; Tien D; Wang Y; Navre M; Patel DV; Sharr MA; DiJoseph JF; Killar LM; Leone CL; Levin JI; Skotnicki JS
Bioorg Med Chem Lett; 1998 May; 8(10):1157-62. PubMed ID: 9871727
[TBL] [Abstract][Full Text] [Related]
10. A quantitative structure-activity relationship study on matrix metalloproteinase inhibitors: piperidine sulfonamide aryl hydroxamic acid analogs.
Kumaran S; Gupta SP
J Enzyme Inhib Med Chem; 2007 Feb; 22(1):23-7. PubMed ID: 17373543
[TBL] [Abstract][Full Text] [Related]
11. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
[TBL] [Abstract][Full Text] [Related]
12. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
[TBL] [Abstract][Full Text] [Related]
13. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
Scozzafava A; Supuran CT
J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
[TBL] [Abstract][Full Text] [Related]
15. A quantitative structure-activity relationship study on some novel series of hydroxamic acid analogs acting as matrix metalloproteinase inhibitors.
Kumaran S; Gupta SP
Med Chem; 2007 Mar; 3(2):167-73. PubMed ID: 17348854
[TBL] [Abstract][Full Text] [Related]
16. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
Fray MJ; Burslem MF; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
[TBL] [Abstract][Full Text] [Related]
19. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases.
Krumme D; Wenzel H; Tschesche H
FEBS Lett; 1998 Oct; 436(2):209-12. PubMed ID: 9781680
[TBL] [Abstract][Full Text] [Related]
20. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
